Literature DB >> 8067777

Influence of diet on experimental toxicity of amphotericin B deoxycholate.

P Chavanet1, V Joly, D Rigaud, J Bolard, C Carbon, P Yeni.   

Abstract

The effects of pre- and postprandial levels of lipids in serum on the experimental in vivo and in vitro toxicities of amphotericin B deoxycholate (AmB-d) were studied. Normal OF1 mice were tested at baseline, after normal feeding, after 3 h of fasting, or after a sequence of feeding and fasting and vice versa. The 50% lethal dose (LD50) of AmB-d was significantly higher in fed mice than in mice which fasted or at baseline (2.38 +/- 0.12 versus 1.53 +/- 0.2 and 1.50 +/- 0.1 mg/kg of body weight, respectively; P < 0.05). When different nutritional regimens were alternated over a short period, the level of in vivo AmB-d toxicity was dictated by the last feeding regimen. Serum triglycerides, but not cholesterol in very-low-density and low-density lipoproteins, correlated significantly (P < 0.01) with the LD50 of AmB. In vitro experiments showed that the addition of human serum reduced AmB-d-induced toxicity against human erythrocytes, but serum drawn after fasting was less protective than postprandial serum. However, neither serum decreased the in vitro activity of AmB-d against Candida albicans. Circular dichroism, a method that enables the amount of free AmB to be measured, showed that both mouse and human total serum lipoproteins bound more AmB-d when serum was isolated postprandially than when it was obtained after fasting. Our results show that AmB-d toxicity is reduced by feeding-induced modifications in serum lipids. The influence of food intake on the clinical toxicity of the drug merits being investigated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8067777      PMCID: PMC188134          DOI: 10.1128/AAC.38.5.963

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Risk factors for Amphotericin B-associated nephrotoxicity.

Authors:  M A Fisher; G H Talbot; G Maislin; B P McKeon; K P Tynan; B L Strom
Journal:  Am J Med       Date:  1989-11       Impact factor: 4.965

Review 2.  Amphotericin B: delivery systems.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

3.  Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats.

Authors:  K M Wasan; K Vadiei; G Lopez-Berestein; D R Luke
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

4.  Effects of serum lipoproteins on damage to erythrocytes and Candida albicans cells by polyene antibiotics.

Authors:  J Brajtburg; S Elberg; G S Kobayashi; G Medoff
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

5.  Effects of the detergent sucrose monolaurate on binding of amphotericin B to sterols and its toxicity for cells.

Authors:  I Gruda; E Gauthier; S Elberg; J Brajtburg; G Medoff
Journal:  Biochem Biophys Res Commun       Date:  1988-08-15       Impact factor: 3.575

6.  One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium.

Authors:  J Bolard; P Legrand; F Heitz; B Cybulska
Journal:  Biochemistry       Date:  1991-06-11       Impact factor: 3.162

7.  Circular dichroism for the determination of amphotericin B binding to liposomes.

Authors:  S Jullien; A Vertut-Croquin; J Brajtburg; J Bolard
Journal:  Anal Biochem       Date:  1988-07       Impact factor: 3.365

8.  Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.

Authors:  R L Juliano; C W Grant; K R Barber; M A Kalp
Journal:  Mol Pharmacol       Date:  1987-01       Impact factor: 4.436

9.  Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers.

Authors:  V L Kan; J E Bennett; M A Amantea; M C Smolskis; E McManus; D M Grasela; J W Sherman
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

10.  Serum lipoprotein and apolipoprotein profiles of the genetically obese ob/ob mouse.

Authors:  M C Camus; R Aubert; F Bourgeois; J Herzog; A Alexiu; D Lemonnier
Journal:  Biochim Biophys Acta       Date:  1988-07-01
View more
  15 in total

1.  Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits.

Authors:  E H Kwong; M Ramaswamy; E A Bauer; S C Hartsel; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  The effect of serum albumin on amphotericin B aggregate structure and activity.

Authors:  S C Hartsel; E Bauer; E H Kwong; K M Wasan
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

3.  Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form.

Authors:  B Baas; K Kindt; A Scott; J Scott; P Mikulecky; S C Hartsel
Journal:  AAPS PharmSci       Date:  1999

4.  Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.

Authors:  M Ramaswamy; K D Peteherych; A L Kennedy; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma.

Authors:  M Ramaswamy; T L Wallace; P A Cossum; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine.

Authors:  K M Wasan; P H Pritchard; M Ramaswamy; W Wong; E M Donnachie; L J Brunner
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

7.  Heat-treated Fungizone retains amphotericin B antifungal activity without renal toxicity in rats infected with Aspergillus fumigatus.

Authors:  Olena Sivak; Karen Bartlett; Kishor M Wasan
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

8.  Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.

Authors:  K M Wasan; A L Kennedy; S M Cassidy; M Ramaswamy; L Holtorf; J W Chou; P H Pritchard
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

9.  Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.

Authors:  Verica Risovic; Michael Boyd; Eugene Choo; Kishor M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Influence of the freeze-drying process on the physicochemical and biological properties of pre-heated amphotericin B micellar systems.

Authors:  Scheyla D V S Siqueira; Miguel A Silva-Filho; Christian A Silva; Ivonete B Araújo; Acarilia E Silva; Matheus F Fernandes-Pedrosa; Anselmo G Oliveira; E Sócrates T Egito
Journal:  AAPS PharmSciTech       Date:  2014-02-08       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.